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Drug adherence in patient group with Parkinson disease 
Background Patients with Parkinson’s disease needs medicines administered frequently to 
manage their condition and maintain their quality of life. Poor medicine adherence may 
influence health negatively, and cause an unnecessary medicine wastage. It is therefore 
important that they are effectively supported to ensure that they adhere to their medicine 
regime.  
 
The aim of the study is to identify barriers to medicine adherence in patients with 
Parkinson’s disease or Parkinsonism and to identify interventions to improve medicine 
adherence. 
 
Method A postal questionnaire containing 39 statements was sent to 430 patients. The 
statements were used to identify patient barriers to adherence. A focus group consisting of 
healthcare professionals discussed interventions to improve medicine adherence. 
 
Results 229 (53,3%) patients responded to the questionnaire. The main barriers to adherence 
are; having enough time with doctor and pharmacist; being requested to attend to follow-up 
sessions; knowing where to get help if needed; having the ability to solve problems appearing 
when taking medicines; worry about side-effects; feeling that taking medicines is a burden 
and knowing enough about their medicines to decide whether to take them. Disease length did 
not relate to the responded barriers to non-adherence. Motivation- intention and ability to 
remember- to take medicines are important barriers to non-adherence.  
 
Conclusion There are several barriers to medicine adherence in the study population, 
indicating there is a need for interventions from healthcare professionals to improve 
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Abbreviations and explanations 
PD: Parkinson’s disease 
L-dopa: Levodopa.  
DDC: Dopa Decarboxylase 
DDCI: Dopa Decarbocylase Inhibitor 
CNS: Central Nervous System 
PNS: Peripheral Nervous System 
COMT- Catechol-o-methyltransferase Inhibitors 
BBB- Blood-Brain Barrier 
MAO-B- Monoamine Oxidase B 



















1.1 Parkinson’s disease 
Pathology 
Parkinson’s disease (PD) is a neurodegenerative disease with an unknown underlying 
pathophysiology. The neurodegeneration consists of selective loss of dopaminergic neurons in 
the substantia nigra (1) which is responsible for co-ordinating the skeletal muscles (2). In 
many neurodegenerative diseases, like PD, there are findings of Lewy bodies and Lewy 
neurites (3). A generally believed hypothesis called the “prion-like” hypothesis, states that 
misfolded α-synucleins produces Lewy bodies and Lewy neurites which leads to neuronal 
death (1). The mechanism is described below.  
 
The mechanism of the “prion-like” hypothesis 
Α-synuclein recruits other similar endogenous proteins (seeding) to self-aggregation like 
prions. These biological cascades (including secretion, uptake and protein seeding) lead to 
pathogenic protein strains that recruits endogenous soluble proteins like Lewy bodies and 
Lewy neurites. The pathogenic soluble proteins cause neuronal death. This cascade is an 
important role in the initiation of the progression of the neurodegenerative disorder. It is 
believed that new therapeutic targets involve slowing or stopping this progression (3).  
 
Motoric symptoms 
The neurodegeneration within the substantia nigra may lead to a series of symptoms like 
bradykinesia, rigidity, postural instability and tremor, which are the main symptoms indicated 
in diagnosing PD (4). The definition of the symptoms is summarised in the BMJ (4) and is 








Table 1.1 Key diagnostic factors for Parkinson’s disease  
Motoric symptoms Description 
Resting tremor A 4-6 Hz tremor at rest that disappears while moving. 
The onset is generally asymmetrical. It’s most 
commonly located in the limbs, but may also appear in 
the chin.  
Rigidity Increased resistance within the range of passive 
movement about a joint.  
Postural instability Imbalance or falling. Either detected spontaneously or 
from a test. 
Bradykinesia Delay in initiation of movement, slower movement, 
freezing of gait.  
  
Non-motoric symptoms 
In addition to motoric symptoms, there are many non-motoric symptoms linked to PD. 
Dementia (5-7), depression (8-10) and dysphagia (11, 12) will be discussed further. Patients 
with PD may experience symptoms like cardiovascular complications, dopamine 
dysregulation syndrome (lack of self-control), urinary urge, sexual dysfunction, constipation, 
sweating, insomnia, pain, fatigue and visual disturbances (13) to mention some of them. 
 
Prevalence 
The prevalence of PD in the Norwegian population is about 1% for people between 50-70 
years, and somewhat higher for people over 70 years. It’s assumed that there are between 
6000 and 8000 patients with Parkinson symptoms in Norway (14). 
 
1.2 Treatment 
The aim of the medical treatment of PD is a better life quality and a reduced mortality rate, 
not remission. Up to this date, no medicines stop the progression of the disease. The treatment 
will be initiated when it is considered necessary for the patients. In Norway, it is preferred 
that the treatment will be initiated by, and followed up by, a neurologist (14). 
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As the disease progresses, the patient will experience worsening symptoms and the treatment 
will have a shorter effect on the symptoms than before. Experienced symptoms may not be 
equally strong all the time, meaning they may change rapidly and unexpectedly. This is called 
an “on-off-phenomena” (14). Patients who feel fine, may suddenly experience tremors and 
have difficulties moving. 
 
There are different groups of medicines used for PD where the main goal is to increase the 




Levodopa (L-dopa) is a dopamine precursor which is converted to dopamine by an enzyme 
called Dopa Decarboxylase (DDC). When L-dopa passes the blood-brain barrier (BBB), it can 
be converted into dopamine, replacing the lost dopamine and therefore treating the symptoms 
experienced by the patient. L-dopa is given together with a peripherally acting Dopa 
Decarboxylase Inhibitor (DDCI) like Carbidopa and Benserazide. The DDCIs cannot pass the 
blood-brain barrier like L-dopa, and will only inhibit the conversion to dopamine peripherally. 
The DDCI will increase the amount of L-dopa that reaches the central nervous system (CNS), 
thus allowing the prescriber to reduce the dose (14). 
 
The bioavailability of L-dopa is 90% in combination with a DDCI, and is reduced to a certain 
degree when taken with food. L-dopa tablets should be administered several times a day 
(dependent on the individual dose required) because of the short half-life of 2 hours (14). 
 
Catechol-o-methyltransferase Inhibitors (COMT-inhibitors) 
COMT is an enzyme converting L-dopa and dopamine into inactive metabolites. It is located 
both in the Peripheral Nervous System (PNS) and the CNS. COMT-inhibitors inhibit the 
COMT enzyme and will therefore increase the dopamine level by inhibiting the 
decomposition of L-dopa into inactive metabolites. Patients needing high doses of L-dopa, 
can be given L-dopa together with a COMT-inhibitor and thereby reducing the necessary dose 
of L-dopa. COMT-inhibitors are not used alone. The inactive metabolites of L-dopa compete 
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with the active form to pass the BBB. Inhibiting the degeneration of L-dopa will therefore 
lead to a greater access of active L-dopa to the brain (14). 
 
Monoamine Oxidase B Inhibitors (MAO-B inhibitors) 
MAO-B is also an enzyme metabolising dopamine. MAO-B inhibitors will, like COMT-
inhibitors, increase the level of dopamine. They should preferably be given together with L-
dopa, and has no documented effect alone. Seligiline and Rasagiline are non-reversible MAO-
B inhibitors, while Safinamide is reversible. Seligiline is metabolised to Amphetamine, and 
will sometimes cause excitement, anxiety and insomnia (14). 
 
Dopamine agonists 
Dopamine agonists stimulate the dopamine 2 (D2)-receptors in the striatum selectively. The 
different dopamine agonists may work differently on an individual. If a dopamine agonist 
works inadequately on the patient, it could be beneficial to try a different medicine within this 
medicine group (14). 
 
Anticholinergics 
Anticholinergics are the oldest anti-parkinson medicine used today, and works best for 
tremor, rigidity and slow movement. The use of anticholinergics in Norway is restrictive 
because of the limited effect and severe side-effects. They are most commonly used in 
Parkinsonism caused by other medicines (14). 
 
Summary 
The medicines used for PD treat the symptoms by raising dopamine levels in the Substantia 
Nigra through different mechanisms. Table 1.2 provides a summary of the different medicine 






Table 1.2 Summary of medicine treatment options for Parkinson’s disease in Norway 
(14) 
Medication group Effect Examples  
Dopa/ dopaderivates A dopamine precursor. Adding 
more dopamine. 
Levodopa 
COMT-inhibitors Inhibits decomposition of 
dopamine, thus increasing the 
dopamine level. 
Entekapon, Tolkapon 
MAO-B inhibitors Inhibits decomposition of 
















Side-effects in the medicine treatment of PD appear due to the increased dopamine level, and 
is similar in almost every treatment group. The side-effects, and their severity, will vary 
between individuals. As the neurodegeneration continues, side-effects will appear faster (14). 
Gastrointestinal-, motoric-, cardiac- and neuropsychological side-effects together with 
anticholinergic side-effects will be discussed further, as they are common in PD patients. 
 
Gastrointenstinale side effects (like nausea and vomiting) is a known side-effect of L-dopa 
(14, 15), but can also be a symptom of the disease (16). Gastrointestinal afflictions can be 





Hyperkinesia is also a known side-effect of anti-PD medication (14), and is mentioned in a 
case study where a young male diagnosed with juvenile Parkinsonism reported involuntary 
movements (17). He reacted to L-dopa 100 mg and Benserazide (DDCI) 25 mg. Later he 
experienced the same with L-dopa 500 mg. The immediate reactions were violent movements 
in all 4 extremities followed by lighter symptoms. 
 
Treatment with L-dopa may cause lack of cardiovascular control. A study indicates that L-
dopa treatment could explain low heartbeat and blood pressure (18). This is explained by a 
reduction in number of baroreflex sequences. L-dopa lowers the plasma level of adrenaline 
and noradrenaline which may be related to lowering sympathetic cardiac stimulation (18). 
 
Neuropsychological side-effects are common when a patient uses anti-PD medication for a 
long period of time. Psychotic symptoms (hallucinations, delirium, delusions) appear in 20-
30% of Parkinson patients receiving anti- PD medication, where hallucination is the most 
frequent symptom (19). These side-effects may lead to insomnia in some patients (14). 
Cognitive impairment in elderly patients is a common neuropsychological side-effect (19). 
 
The side-effects of anticholinergic medication are different than the other groups. Dry mouth, 
disturbances in sight, nausea, obstipation and slower emptying of the bladder is common in 
patients using this group of medication. It is not ideal for elderly as they may easily 
experience altered confusion (14). 
 
1.3 The medicine regimen of a PD patient 
Some patients with PD needs medicines multiple times a day. The frequency of dosing and 
the number of medicines may increase with time as effectiveness wears off, which would 
result in a complicated medicine regimen. In these cases, it is important to identify medicine 
non-adherence. This will be discussed further. Comorbidity, the appearance of other diseases 
together with PD, could lead to a necessity of additional medicines which could complicate 




According to a double-blinded study with 441 subjects (2013), PD patients prefer to use 
medication taken once daily instead of three times daily (20). However, decreasing the dosing 
frequency is hard to accomplish considering the treatment options used today. The short half-
life (discussed in chapter 1.2- Treatment of Parkinson’s disease) makes multiple intakes daily 
necessary (21). Patients with moderate- to- advanced stages of PD may need to take up to 5 
different drugs up to about 8 times a day (21). In a study from 2004 using a medication 
questionnaire and a computerized medication event monitoring system (MEMS) to monitor 
medication use, almost 30% of the total 39 patients with PD reported missing at least one of 
their medications. 76,4% reported either missing or mistime doses (22). The main explanation 
why they missed their doses was “being too busy”.  
 
1.4 Adherence 
WHO’s definition of adherence: 
 “the extent to which a person’s behaviour- taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health 
care provider.” (23). 
 
Non-adherence influence the quality of the patient treatment, and may influence health (e.g. 
more intense relapses, increased risk of dependence or increased risk of abstinence- and 
rebound effect) (24). It can also lead to medicine wastage. Paying for wasted medicines and 
paying to treat severe illness due to non-adherence may cause economic wastage (25). 
Generally, non-adherence can be divided into two subdivisions, unintentional non-adherence 
where the patients involuntarily fails to take their medication as prescribed and intentional 
non-adherence where the patient, for some reason, chooses not to take their medications as 
prescribed. 
 
There is a distinct difference between compliance and adherence. A compliant patient is 
expected to comply with instructions, whereas an adherent patient behaves as agreed with the 
prescriber i.e. they are a part of the decision-making progress (23). Today, most prescribers 
focus on adherence instead of compliance. Listening to the patient is essential to take their 
medication as prescribed (26, 27). This way, the provider can determine the patient’s beliefs, 
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concerns, attitudes and expectations about their treatment. Identifying difficulties for the 
individual patient is essential to make tailored interventions. 
 
Problems using the definition “adherence” 
Measuring adherence does not sufficiently identify difficulties using his/her medicines (28). 
Low adherence does not explain what difficulties the patient experiences when taking 
medicines. Detailed questions would provide this information. Therefore, a dialogue with the 
patient would be more important than measuring adherence in other ways. Adherence 
unjustified the patients, and is not always within the control of the provider.  
 
1.5 Unintentional medicinal non-adherence in Parkinson patients 
Unintentional non-adherence describes patients who does not take their medication for 
reasons they cannot control themselves. A patient who forgets to take their medication is a 
common example of unintentional non-adherence. Other reasons can be poor eyesight, lack of 
prehensile power, lack of competence to take their medicine in the correct way (for example 
crushing a modified release tablet) etc.  
 
Dementia 
Dementia is a well- known problem in Parkinson patients. Approximately 29-40% of patients 
with PD also suffer from dementia (5, 6, 29, 30), and according to several studies, it seems to 
be a correlation between dementia and the severity of the symptoms of PD (6, 7, 29). 
Dementia in PD may lead to impairment in planning, abstract thinking, episodic memory and 
attention which may all decrease medicine adherence unintentionally (31). Short term 
memory loss, associated with dementia, diminishes the ability to remember instructions and 
may cause non-adherence. There are studies showing a correlation between PD and cognitive 
impairment (32, 33). This may affect the learning process that is essential in adapting the 





1.6 Intentional medicinal non-adherence in Parkinson patients 
Intentional non-adherence is when the patient voluntarily does not take their medicines as 
prescribed. An example of intentional non-adherence is omitting medicines caused by the fear 
of side-effects. Other reasons may be having limited confidence in the treatment, disliking the 
medication or not trusting the prescriber. 
 
Depression 
Studies have shown that a relative big part (40-68%) of Parkinson patients suffer from 
depression (8, 9, 34). This manifests slightly different from other types of depression, with a 
greater degree of anxiety and a less self-punitive behaviour (9). There are several assumed 
reasons leading to depression amongst this patient group. Studies have suggested uncertainty, 
fatigue, perceived health status (8) and major life events (35). Depression may lead to 
intentional non-adherence in patients with Parkinson’s disease mostly because of the lack of 
motivation or fatigue. It is therefore an important factor that should be screened for in clinical 
settings, though depression is considered maybe the greatest challenge recognising and 
treating in the clinic (10).  
 
Dysphagia 
It is common for patients with PD to experience dysphagia (swallowing problems) (11, 12, 
36). Swallowing is complex and is affected by 25 different muscles and oropharyngeal 
sensory feedback (36). The pathology of dysphagia is poorly understood, but there are 
traditional ideas presented in several studies. A neuroimaging study shows that not only does 
the brainstem and basal ganglia circuits affect swallowing, but also the cortical areas in the 
brain (36). Within PD patients; the dysphagic patients are assumed to lack compensatory 
pathways compared to healthy controls (36).  
 
Dysphagia makes it harder to take oral solid medicine which may influence adherence (37). 
Screening after dysphagia in patients may be important, because they may not report this 
problem to their prescriber. A cohort study comparing thoughts about oral medication in 
patients with and without dysphagia, found out that patients with dysphagia had more 
problems swallowing oral tablets or capsules than patients without dysphagia (38). Generally, 
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patients with dysphagia preferred formulations that are easier to swallow compared to the 
other patient group, where dispersible- or effervescent tablets were the most popular (38). 
Using these types of formulations may alter the adherence in Parkinson patients with 
dysphagia.  
 
1.7 Identifying non-adherence in patients 
Healthcare professionals should identify the cause(s) of non-adherence in individual patients 
to decrease medicine non-adherence. Awareness of existing tools could help healthcare 
professionals identifying non-adherence in the clinic.  
 
Major predictors of non-adherence 
• Psychological problems, particularly depression. 
• Cognitive impairment 
• Asymptomatic disease  
• Inadequate follow-up or discharge planning 
• Side-effects of medication 
• Lack of belief in benefit of the treatment 
• Lack of insight into their illness 
• Poor relationship between patient and provider 
• Presence of barriers to medicine adherence 
• Missed appointments 
• Complexity of treatment 
• Cost of health-related factors (39) 
 
There are many factors leading to non-adherence, and it is hard to mention all of them. WHO 
has come up with examples of these factors, which is divided into 5 subgroup A-E (40). The 
subgroups are presented in the table below (table 1.3). Suggestions for interventions to the 





Table 1.3 WHO’s statements of factors influencing adherence in patients (41)  
 Subgroup Examples 
A Social and economic 
factors 
Poor socioeconomic status, poverty, illiteracy, long distance 
from treatment centre, lack of effective social support, family 
dysfunction, culture and belief about illness etc. 
B Health care team 
and system related 
factors 
Lack of knowledge and training of adherence, patient-provider 
relationship, overworked health care providers, short 
consultations, lack of follow-up etc.  
C Condition related 
factors 
Illness-related demands, severity of symptoms, level of 




Complexity of medical regimen, changes in treatment, duration 
of treatment, beneficial- and side-effects. 
E Patient-related 
factors 
Resources, knowledge, attitudes, beliefs, expectations, 

















Table 1.4 WHO’s statements of interventions influencing adherence in patients (42) 
 Subgroup Interventions 
A Social and 
economic 
interventions 
The policy-makers managing the health care environment must 
find difficulties regarding the social and economic factors to find 
interventions that are relevant to them. Examples: reducing 
poverty by selling medicines with affordable prices or enhancing 
social support by introducing community-based organizations. 
B Health care team 
and system related 
interventions 
Training in adherence-management for providers, making an 
adherence counselling toolkit adaptable for different patients, 
suggesting interventions and follow up adherence. 
C Condition related 
interventions 
Healthcare professionals should identify disease-specific 
demands, symptoms and impairments and identify co-morbidities 
(like anxiety and depression).  
D Therapy-related 
interventions 




Development of self-management interventions (like an 
organisation group) to improve motivation and increase patient 
education about medicines and behavioural self-regulation 
strategies.  
 
1.8 Measuring and analysing adherence 
Measuring adherence can be done after screening for- and proposing interventions to the 
causes of non-adherence. A measure of non-adherence can be useful to identify the need of 
follow-up consultations. There are two main ways to measure adherence; direct measures and 
indirect measures (43). The direct measures consist of observation of medication intake and 
biological assay of drug levels in the blood or metabolites (in either blood or urine). Indirect 
measures include self-reports (from patient or relatives/clinicians), pill counts, fill frequency 
of prescriptions, electronic monitoring etc. Observation of medicine intake is the only 
measuring method that verifies adherence, and would be optimal to in the clinic (43).  It is 
important to think about what type of measuring method we use to address non-adherence. 
There is no method without disadvantages, and therefore both advantages and disadvantages 
should be considered before choosing a method. A summary of the most common measuring 
methods is addressed in the table below. 
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Table 1.5 Advantages and disadvantages of different adherence measuring methods (43) 
Measuring method Advantage Disadvantage 




Needs a direct patient- 
clinician contact 
(impractical).  
Patients can hide the pills in 
the mouth and discard them. 
Measurement of levels of 
medication in the blood/ 
measurements of medication 
metabolites in blood/urine 
Objective measurement Need a direct patient-
clinician contact.  
Variation in 
pharmacokinetics. Expensive.  
Self-reporting Inexpensive/ easy to 
accomplish 
Recall/ social desirability 
response bias 
Fill frequency of 
prescriptions 
Objective measurement 
(can also be used in 
placebo controls). 
Requires complete pharmacy 
records, which is hard to 
achieve after a large amount 
of time. 
Pill counts (pills collected, 
remaining or prescribed) 
Objective, inexpensive, 
quantifiable 
Does not work if the patient 
is hoarding or discarding 
medicine. 
Electronic monitoring Detailed measures, easily 
quantified  
Expensive. Requires a certain 
contact with the clinic. 
Patient may not take the 
medication or take the wrong 








1.9 Health behaviour 
As PD is a chronic disease, it requires a certain life style (health behaviour) to improve long 
term medicine adherence. Changing health behaviour is hard and takes a lot of work. When a 
patient is sick, working is hard and learning is harder (44). However, there are several ways to 
handle this issue. Healthcare professionals can influence the patient’s behaviour using 
techniques based on the theory of health behaviour change (45). 
 
The theory of health behaviour change, The HAPA model  
The Health Action Process Approach (HAPA) is a model providing theory about health 
behaviour change (45). This section is based on the article written by Schwarzer, R., Lippke, 
S., & Luszczynska, A. (2011). 
 
There are two different types of models that can be used to describe the theory of health 
behaviour change; the continuum model and the stage model. In the continuum model, 
patients are moved along a range where the likelihood of action increases. TPB (Theory of 
Planned Behaviour), SCT (Social-Cognitive Theory) and PMT (Protection Motivation 
Theory) are three theories based on a continuum model. In the stage model, patients need to 
go to the first stage before they can move to the next one. There are limitations using both 
models. The continuum model is useful to explain and predict a person’s behaviour, while the 
stage model is useful to adapt interventions to the individual. The Health Action Process 
Approach (HAPA) includes both a continuum model and a stage model.  
 
To change health behaviour, the patient needs to have the intention to perform a behaviour 
change (motivational phase), and the patient needs to perform, and maintain, the behaviour 
change (volitional phase). The volitional phase is the actual behaviour changing phase. People 
going through a health behaviour change has a changing mindset, and the model is therefore 
divided into three phases representing three different mindsets. The motivational phase 
includes Preintenders, while the volitional phase includes Intenders and Actors. This will be 




Figure 1.1 The theory of health behaviour changes in a chronic disease (45). 
 
Motivational phase 
Before a person can change their behaviour, they need the intention to do so. This is the 
greatest challenge in changing health behaviour. People in this phase are called Preintenders 
(see figure 1.1), and are influenced by three factors (shown in circles in figure 1.1); Task self-
efficacy, outcome expectancies and risk perception. Task self-efficacy means that the person 
believe that they can perform a specific behaviour change, outcome expectancies means the 
persons expectations of performing the behaviour change and risk perception means the 
understanding of the risks of not performing the behaviour change. 
 
Volitional phase 
When a person intends to change their behaviour, they need to perform it. In this phase, there 
are two different mindsets; the Intenders intend to change their behaviour, but does not 
actually perform. The Actors intend, and change their behaviour. It is important to separate 
people with different mindsets into different phases, as interventions are easier to adapt to the 
individual person. When a person has changed their behaviour, it needs to be maintained. 
Planning is important to Intenders, as they intend to change their behaviour but lacks the 
skills to do so. Planning can be divided into action planning (when, where and how to 
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perform) and coping planning (help to perform despite the restrains). Action control is 
important to Actors. Action control means that the behaviour change performed is compared 
to the standard behaviour, thus providing self-awareness. The belief that they can maintain 
(maintenance self-efficacy), and recover (recovery self-efficacy) the behaviour change is 
important in this phase. Social support can act as a resource if provided or a barrier if not 
provided, and will influence the volitional phase. It can be divided into instrumental-, 
emotional- and informational support.  
 
1.10 Previous studies regarding PD and adherence 
The previous studies done on PD patients in relation with adherence has mainly been focusing 
on measuring adherence in patients. Additionally, patient demographics has been presented in 
more detail using scales. UPDRS (Unified Parkinson's disease rating scale), Mini-mental, 
geriatric depression scale etc. is commonly used. 
 
Only a few studies have been searching for causes of non-adherence in PD patients. A 
qualitative study based on semi-structured interviews with PD patients is one of them (46). It 
was concluded in the study that memory failure mostly led to minor unintentional non-
adherence. Examples of minor intentional non-adherence were also mentioned, like patients 
tailoring their medicines to support their lifestyle e.g. taking all of the medicines to let them 
go dancing. Patients were familiar with their treatment goals, but did not seem to understand 




IMAB-Q, The Identification of Medicine Adherence Barriers Questionnaire is a questionnaire 
designed by Dr Claire Easthall for her PhD project supervised by Dr Debi Bhattacharya, 
UEA, England, used for identifying barriers in medicine adherence.  
 
There are two different versions of the questionnaire, IMAB-Q 10 with 10 statements and 
IMAB-Q 30 with 30 statements. The IMAB-Q 30 is used for research, while the IMAB-Q 10 
is used in the clinic. This questionnaire is formulated in English in a patient-friendly way, to 
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enable patients to complete them on their own. Patients check off whether they agree or 
disagree. In total they have 5 choices (strongly agree, agree, neither agree nor disagree, 
disagree, strongly disagree). 
 
There are no gold standard on interventions to improve adherence today, and the aim of the 
IMAB-Q is to identify effective interventions (47). Each barrier is linked to the relevant 
domains of the Theoretical Domains Framework (TDF) which contains health behaviour 
changing techniques based on many different psychological theories. By using the IMAB-Q 
in the clinic, practitioners can identify and motivate patients to adhere to their medication. 
 
1.12 Summary 
PD is a neurodegenerative disease where medicine treatment is used to increase dopamine in 
Substantia Nigra and thereby decrease symptoms of the disease. Many side-effects may 
appear during the treatment due to the increased dopamine level. Patients need medicines 
administered frequently to manage their condition and maintain quality of life. Due to the 
necessity of frequent doses, the medicine regimen can be complicated. PD patients often 
experience co-morbidities like depression and dementia, which may increase the number of 
medicines needed and increase the complication of their medicine regime. Medicine 
adherence is achieved when the patient behaviour corresponds with the agreed treatment. 
Non-adherence can be subdivided into intentional (voluntary)- and unintentional (involuntary) 
medicine adherence. As PD is a chronic disease, adherence is important to identify and 
improve health and reduce medicine wastage. Health behaviour changing techniques can be 
used to improve non-adherence, which should be used by healthcare professionals in the 
clinic. Effective interventions to the barriers to adherence should be identified, and the IMAB-
Q is a tool aiming to help practitioners identify this in the clinic. 
 
1.13 The aim of the master thesis 
The aim of this master thesis is; 
• To identify barriers to medicine adherence in Norwegian patient group with 
Parkinson’s disease or Parkinsonism.  
• To identify interventions to improve medicine adherence in a focus group consisting 




2.1 Study method 
The study consists of a retrospective survey of post-discharge patients with PD or 
Parkinsonism to identify barriers to non-adherence, and a focus group consisting of healthcare 
professionals to identify interventions to the barriers.  
 
2.2 Questionnaire design and covering letter 
The questionnaire is categorized into 3 major topics; barriers to adherence directly influenced 
by information and follow-up of health personnel, you and your medicines (IMAB-Q 30) and 
personal information. Personal information includes questions regarding gender, disease 
length and number of medicines. 
 
The IMAB-Q 30 was translated from English to Norwegian by the main researcher with help 
from the Norwegian supervisor. 
 
Statements based on the theory of health behaviour change in patients with a chronic disease 
(HAPA model, section 1.9), was added as this was considered important to the study. The 














Table 2.1 Statements added by the researcher 
Number Statements Factors influencing 
health behaviour 
1 I have a good relationship with my doctor(s) who 
prescribed my medication 
Emotional support 
2 I have enough time to talk to my doctor about my 
medication 
Informational support 
3 I have enough time to talk to the pharmacist at the 
pharmacy about my medication 
Informational support 
4 I made a plan with my doctor about my future 
medicine use 
Action planning 
5 I understand why I need my medicine(s) Outcome expectancy 
6 I expect my medicines to help me for my disease Outcome expectancy 
7 I know the risk of not taking my medication(s) Risk perception 
8 I have been requested to come to follow-up 
consultations to discuss my medicine use 
Informational support 
9 If problems appear with my medicine use (i.e. 
forget to take the, or get difficulties swallowing 














The original statements are based on the behavioural domains from the TDF explained in 
section 1.11 (47). 
Table 2.2 Original IMAB-Q statements  
Number Statements Behavioural domain 
1 I know how to take my medicines as 
prescribed 
Knowledge 
11 I know enough about my medicines to 
decide whether to take them 
Knowledge 
21 I have the information that I need to be 
able to easily order and collect my 
prescriptions 
Knowledge 
2 I am physically able to take my medicines 
as prescribed 
Skills 
12 I have a system in place to help me order, 
collect and take my medicines as 
prescribed 
Skills 
22 Telling my medicines apart from each 
other would not be a problem for me 
Skills 
3 I remember to take my medicines as 
prescribed 
Memory, attention and  
decision making processes 
13 I am easily distracted from taking my 
medicines 
Memory, attention and  
decision making processes 
23 I remember to order and collect my 
medicines on time 
Memory, attention and  
decision making processes 
4 I trust my doctor(s) with decisions about 
my healthcare 
Social influences 
14 If I needed support from others to take my 




24 I worry about what other people would 
think of me if they know I took medicines 
Social influences 
5 I can easily get hold of my prescribed 
medicines from the pharmacy 
Environmental constraints 
15 Changes to my daily routine would not 
interfere with taking my medicines as 
prescribed 
Environmental constraints 
25 My pharmacy provides efficient service for 
ordering and collecting my medicines 
Environmental constraints 
6 I have negative emotions (e.g. frustration, 
embarrassment, anger) about taking my 
medicines as prescribed. 
Emotions 
16 Taking my medicines as prescribed is an 
unwelcome reminder of my condition 
Emotions 
26 Taking my medicines as prescribed is a 
burden to me 
Emotions 
7 I am motivated to take my medicines as 
prescribed 
Motivation & goals 
17 Taking my medicines as prescribed is high 
on my list of priorities 
Motivation & goals 
27 I intend to take my medicines as prescribed Motivation & goals 
8 I do not have to choose between paying for 
my prescriptions and paying for other 
things that are important to me 
Goal conflicts 
18 Taking my medicine as prescribed does not 
fit with my daily routine 
Goal conflicts 
28 Life gets in the way of me taking my 




9 I feel confident about all aspects of 
managing (ordering, collecting and taking) 
my medicines 
Beliefs about capabilities 
19 I am confident that I could find ways to 
solve any difficulties that I have with 
taking my medicines as prescribed 
Beliefs about capabilities 
29 I don't think I could cope if my medication 
regime kept changing 
Beliefs about capabilities 
10 I worry about the unwanted effects (e.g. 
harmful effects or side effects) of taking 
my medicines 
Beliefs about consequences 
20 If I don't take my medicines as prescribed I 
think my condition will get worse 
Beliefs about consequences 
30 I have my reasons for not taking my 
medicines as prescribed 
Beliefs about consequences 
The translated questionnaire can be found in Appendix A. 
 
The covering letter was designed to increase response rate with focus on short, specific 
information.  
 
Some actions were done to increase the response rate further. These actions are based on 
evidence from a Cochrane review comparing different techniques (48): 
- Ensured an interesting questionnaire topic 
- Kept the questionnaire as short as possible 
- Provided university logo on the envelope and at the start of the questionnaire 
- Provided a stamped return envelope 
- Assured confidentiality 
- Use of coloured headings and a relevant image on the covering letter 
- Providing short instructions on the front page of the questionnaire 
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2.3 Selection of participants 
The inclusion criteria used in this study are; Patients treated at Haukeland hospital from 
January to July 2017 diagnosed with Parkinson’s disease (Classified as ICD-10 G20 in 
Norway). From the neurological ward at Haukeland, the Norwegian supervisor accessed a list 
consisting of names and addresses to patients who met the inclusion criteria, in total 600 
patients. The list was immediately erased after sending out the envelopes.  
 
Sample size justification 
A sample size of 400 patients would provide 95% Cis of ±4% around a proportion of 80%.  





To test if the translation was understandable, we asked 9 patients visiting the hospital 
pharmacy at Haukeland hospital to read through the questionnaire and give feedback whether 
they understood the questions. The patients focused on different sections rather than the 
whole questionnaire, and gave positive feedback in general. 
 
The recommended changes were: 
- Specify the language to avoid confusion. 
- Changes in the structure of the sentences to make the statements easier to read 
- Clarify small words that could mean different things 
- Ensure that the headlines (totally agree, agree etc.) are on top of every section of the 
questionnaire 
Recommendations and feedback was discussed with the supervisor and used to improve the 





From the list received from the neurological department, 30 patients with names starting with 
different letters was sampled into a pilot group. The aim of the pilot group was to check how, 
and how many, patients responded. A blank space allowing patients to comment on the 
questionnaire or give relevant feedback was included to enhance face validity. As the 
response rate was appropriate and patients generally responded to the different statements, we 
considered the questionnaire to be understandable for the patients.  
 
Adjustments to increase quality of the questionnaire 
Two patients in the pilot group stated that they did not have Parkinson’s disease. We 
discussed this with the head neurologist at Haukeland, who confirmed that because of lack of 
time, neurologists usually use the diagnose code ICD-10 G20 for patients with Parkinsonism 
as well. As our inclusion criteria was G20, we changed the title from “Medicine use in 




To make sure we covered all relevant barriers to adherence, we used a validated tool. The 
IMAB-Q provides structural validity using Mokken analysis (47). 
 
2.5 Main study 
For the main study, the first 400 patients on the list were chosen. We excluded patients who 
participated in the pilot study, ensuring no patients would receive the questionnaire twice. 
 
2.6 Coding quantitative data 
SPSS was used to analyse the results. Statements with no response were coded 999. 
Responses that were impossible to analyse (for example both agree and disagree, or answers 
in text format) were coded 777. If the respondent checked off two boxes next to each other 
(i.e. both “strongly agree” and “agree”), the most negative response was chosen (in this case 
“agree”). The mean value was chosen in interval responses to “Duration of the disease” 
(Question 41). The highest number has been chosen in interval responses to “Number of 
medicines” (Question 42). Vitamin supplements was excluded from the data. Some new 
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variables were made; “Newly diagnosed patients” is defined as “Disease length” (Question 
41) less than 2 years. Dichotomous statements were defined “Yes” if patients agreed and 
“No” if patients were unsure or disagreed. 
 
Creation of dichotomous variables 
The following barriers from the IMAB-Q has been dichotomised and included in figure 3.6-
3.9 
- I worry about the unwanted effects (e.g. harmful effects or side effects) of taking my 
medicines 
- I am confident that I could find ways to solve any difficulties that I have with taking 
my medicines as prescribed 
- If I needed support from others to take my medicines as prescribed, I could get it 
- I trust my doctor(s) with decisions about my healthcare 
- I know enough about my medicines to decide whether to take them 
- I have a system in place to help me order, collect and take my medicines as prescribed 
- Changes to my daily routine would not interfere with taking my medicines as 
prescribed 
 
The following barriers from the IMAB-Q has been dichotomised and included in figure 3.10 
- I have enough time to talk to my doctor about my medication 
- I have enough time to talk to the pharmacist at the pharmacy about my medication 
- I have been requested to come to follow-up consultations to discuss my medicine use 
- I know the risk of not taking my medication(s) 
- If problems appear with my medicine use (i.e. forget to take the, or get difficulties 
swallowing them) I know where to get help 
- I am confident that I could find ways to solve any difficulties that I have with taking 
my medicines as prescribed 
- I worry about the unwanted effects (e.g. harmful effects or side effects) of taking my 
medicines 
- Taking my medicines as prescribed is a burden to me 
- Taking my medicines as prescribed is an unwelcome reminder of my condition 
- I remember to order and collect my medicines on time 
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- I trust my doctor(s) with decisions about my healthcare 
- I know enough about my medicines to decide whether to take them 
- Taking my medicine as prescribed does not fit with my daily routine 
- I don't think I could cope if my medication regime kept changing 
 
Table 2.1 Statistical tests performed 
 Reference to results Statistical test used 
Comparison of potential 
barriers from the IMAB-Q 
and direct influence of 
health personnel 
(dichotomised variables) 
Figure 3.6- 3.9 Fisher’s exact test 
Comparison of the most 
frequent barriers between 
newly diagnosed patients 
and patients diagnosed for a 
longer time 
(dichotomised variables) 
Figure 3.10 Fisher’s exact test 
Comparison of motivation, 
intention and ability to 
remember medicines with 
potential barriers from the 
IMAB-Q 
Table 3.2- 3.5 Spearman’s rank correlation 
 
2.7 Qualitative analysis of comments from the questionnaire 
Textual comments regarding the healthcare system was transcribed into Excel verbatim. 
These were read carefully and the placed into common themes, in total 14 subgroups. The 
subgroups were put together into 4 main groups. Answers were shortened for readability. The 




2.8 Qualitative analysis of focus group results 
A focus group is a qualitative method where 4-12 people participate to a semi-structured 
discussion, where a facilitator follows a set of topics and asks broad questions to start the 
discussion (49). Even though the participants present their individual experiences and 
opinions, they are encouraged to interact with each other. Knowledge can therefore be seen 
from different perspectives (49, 50). 
 
The aim of the focus group was to discuss interventions that could be taken by healthcare 
professionals to improve adherence in PD patients based on the identified barriers. As we 
wanted a discussion of their individual thoughts and ideas, a focus group was decided as a 
suited method. We wanted to gather 2-3 doctors, 1-2 nurses, 1 clinical pharmacist and 1 
community pharmacist as this would represent a variety of healthcare professionals to discuss 
the different aspects of the treatment of PD patients.  
 
The main researcher, the student, was the facilitator in the focus group while the supervisor 
was a moderator. The meeting was done in Norwegian, as all participants were Norwegian. 
None of the researchers participating in the focus group was experienced clinical researchers. 
The moderator provided a meeting location at her workplace with a projector and space for 
the participants to feel comfortable.  
 
The head neurologist of the neurological department and the hospital pharmacist acted as 
gatekeepers to recruit participants to the focus group. The community pharmacist was 
recruited by the main researcher from a pharmacy known by the researcher prior to the study. 
Participants were recruited by e-mail, receiving a written invitation attached. 
 
A handout was given 6 days ahead of the meeting with a short presentation of the themes we 
were going to discuss, allowing the participants to prepare themselves and come up with ideas 
before the focus group meeting.  
 
The moderator took notes during the focus group, and the notes were discussed with the 
moderator after the meeting was done. Different themes derived after discussing the focus 
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group data. We validated the results by sending the notes back to the participants, asking them 
if the notes reflected the conversation or not, and giving an opportunity to add further 
comments. No changes were needed. 
 
The topics presented to the focus group were based on figure 3.1-3.5: 
- Information and follow-up of health personnel 
- Patients’ attitude and thoughts about medicines 
- Handling medicines 
- Patient routines 
 
Data was classified into four different themes: 
- Better information 
- Use of time 
- Conversation skills 
- Practical actions 
 
2.9 Summary 
• A retrospective survey was used to identify barriers to non-adherence. The tool has 
been validated, thus providing content validity. Face validity is enhanced by piloting 
the survey.  
• A focus group containing healthcare professionals was put together, where the head 
neurologist of the neurological department and the hospital pharmacist, acted as 
gatekeepers to recruit participants. The main researcher recruited the community 
pharmacist. 
• The inclusion criteria are; Patients treated at Haukeland hospital from January to July 
2017 diagnosed with Parkinson’s disease or Parkinsonism (G20). 
• Textual comments regarding the healthcare system was transcribed verbatim into 
Excel and sorted into 4 main groups. 
• The facilitator and moderator discussed the notes derived from the focus group 





We applied to REK (Regional ethics committee) in Norway, as this project is considered a 
























3.1 Quantitative results 
Table 3.1 presents the demographics of the study population. 430 questionnaires in total were 
sent out. The response rate in both pilot group (16 responses) and main study (213 responses) 
was 53,3%. The results from the pilot group was included in the study.  
 
Table 3.1 Patient demographics 
 Measure Study population (n=229) 
How many replied in pilot group n (%) 16 (53,3 %) 
How many replied in main study n (%) 213 (53,3%) 
Gender: Male % 64,4% 
Length of disease Median 
(IQ) 
6 years (3,10) 


















All statements from the questionnaire has been presented in figure 3.1-3.5, describing the 
frequency of the different barriers. 
 
Figure 3.1 and 3.2 describes patient responses on information and follow-up of health 
personnel. Many patients have a good relationship with their doctor. Almost one third did not 
plan their further medicine use or have enough time to talk to their doctor about their 
medication. This is greater with respect to pharmacists.  
 










0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
I have enough time to talk to the pharmacist at
the pharmacy about my medication
I have enough time to talk to my doctor about
my medication
I made a plan with my doctor about my future
medicine use
I have a good relationship with my doctor(s)
who prescribed my medication
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
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Patients generally understand why they need their medicines and expect them to work. Some 
patients do not know the risk of omitting their medicines. A significantly smaller proportion 
of the study population knows where to get help if needed and have been requested follow-up 
consultations. 
 











0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
I have been requested to come to follow-up
consultations to discuss my medicine use
If problems appear with my medicine use (i.e
forget to take the, or get difficulties swallowing
them) I know where to get help
I know the risk of not taking my medication(s)
I expect my medicines to help me for my
disease
I understand why I need my medicine(s)
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
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Figure 3.3 represents the medicine thoughts and attitudes of the study population. Their 
intentions to take medicines seems good, they seem motivated and they prioritise to take their 
medicines. Side-effects are a topic of concern for a big part of the study population. Taking 
medicines seems to be a burden and an unwelcome reminder of their disease in some patients. 
 




0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
I worry about what other people would think of
me if they know I took medicines
I have my reasons for not taking my medicines
as prescribed
I have negative emotions (e.g. frustration,
embarrassment, anger) about taking my
medicines as prescribed.
Taking my medicines as prescribed is an
unwelcome reminder of my condition
Taking my medicines as prescribed is a burden to
me
I worry about the unwanted effects (e.g. harmful
effects or side effects) of taking my medicines
If I don't take my medicines as prescribed I think
my condition will get worse
I am motivated to take my medicines as
prescribed
Taking my medicines as prescribed is high on my
list of priorities
I intend to take my medicines as prescribed
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
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Figure 3.4 represents the responses regarding the handling of medicines. Most patients know 
how to take their medicines, and are physically able to take them. However, remembering to 
order and collect medicines in time seems to be a problem for some of the patients. A 
reasonably big part of the population does not trust their doctor’s decisions about their 
healthcare, and have trouble finding help and solving difficulties that may arise. Few knows 
enough about their medicines to decide whether to take them. 
 
Figure 3.4 Handling medicines 
 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
I am easily distracted from taking my medicines
I know enough about my medicines to decide
whether to take them
If I needed support from others to take my
medicines as prescribed, I could get it
I am confident that I could find ways to solve
any difficulties that I have with taking my
medicines as prescribed
I trust my doctor(s) with decisions about my
healthcare
Telling my medicines apart from each other
would not be a problem for me
I remember to take my medicines as prescribed
I remember to order and collect my medicines
on time
I know how to take my medicines as prescribed
I am physically able to take my medicines as
prescribed
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
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Figure 3.5 represents the influence of the patients’ routines on taking their medicines. The 
practical routines of ordering and collecting their medicines is manageable for the study 
population, even though few patients have a system to order, collect and take their medicines. 
It seems like they have been receiving sufficient information within this topic. Almost one 
third had to choose between paying for their prescriptions and paying for other important 
things. Their daily routines concerning their medicine use seems harder to manage, and a 
change in their daily routine would influence their medicine use in a lot of cases. 
 
Figure 3.5 Patient routines 
 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Life gets in the way of me taking my medicines as
prescribed
Taking my medicine as prescribed does not fit
with my daily routine
I don't think I could cope if my medication
regime kept changing
Changes to my daily routine would not interfere
with taking my medicines as prescribed
I have a system in place to help me order, collect
and take my medicines as prescribed
I do not have to choose between paying for my
prescriptions and paying for other things that are
important to me
I can easily get hold of my prescribed medicines
from the pharmacy
I feel confident about all aspects of managing
(ordering, collecting and taking) my medicines
My pharmacy provides efficient service for
ordering and collecting my medicines
I have the information that I need to be able to
easily order and collect my prescriptions
Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree
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The barriers presented in figure 3.6- 3.9 has been dichotomised as explained in section 2.6. 
Fisher’s exact test has been used to identify statistical differences between the groups. 
 
Figure 3.6 provides a comparison between the responses to barriers from figure 3.1 and 
whether patients reported having a good relationship with their doctor or not. Those who 
reported a good relationship with their doctor were more likely to trust their doctor and less 
likely to worry about side effects. 
 
Figure 3.6 Comparison of patients with and without a good relationship with their 
doctor 
* Significant at 0,05 level ** Significant at 0,01 level 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
I worry about the unwanted effects (e.g.
harmful effects or side effects) of taking my
medicines
I am confident that I could find ways to solve
any difficulties that I have with taking my
medicines as prescribed
If I needed support from others to take my
medicines as prescribed, I could get it
I trust my doctor(s) with decisions about my
healthcare
I know enough about my medicines to decide
whether to take them
I have a system in place to help me order,
collect and take my medicines as prescribed
Changes to my daily routine would not
interfere with taking my medicines as
prescribed
I have a good relationship with my doctor(s) who prescribed my medication





Figure 3.7 provides a comparison between the responses to barriers from figure 3.1 and 
whether patients reported enough time with their doctor or not. Patients who reported having 
enough time with their doctor were more likely to trust their doctor, more likely to get support 
taking their medicines and less likely to worry about side effects. 
  
Figure 3.7 Comparison of patients with and without enough time with their doctor 






0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
I worry about the unwanted effects (e.g. harmful
effects or side effects) of taking my medicines
I am confident that I could find ways to solve any
difficulties that I have with taking my medicines
as prescribed
If I needed support from others to take my
medicines as prescribed, I could get it
I trust my doctor(s) with decisions about my
healthcare
I know enough about my medicines to decide
whether to take them
I have a system in place to help me order, collect
and take my medicines as prescribed
Changes to my daily routine would not interfere
with taking my medicines as prescribed
I have enough time to talk to my doctor about my medication






Figure 3.8 provides a comparison between the responses to barriers from figure 3.1 and 
whether patients reported enough time with their pharmacist or not. Patients who reported 
having enough time with their pharmacist were more likely to trust their doctor, more likely to 
get support taking their medicines and more likely to be able to solve any difficulties 
regarding their medicine regime. 
 
Table 3.8 Comparison of patients with and without enough time with the pharmacist 





0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
I worry about the unwanted effects (e.g.
harmful effects or side effects) of taking my
medicines
I am confident that I could find ways to solve
any difficulties that I have with taking my
medicines as prescribed
If I needed support from others to take my
medicines as prescribed, I could get it
I trust my doctor(s) with decisions about my
healthcare
I know enough about my medicines to decide
whether to take them
I have a system in place to help me order,
collect and take my medicines as prescribed
Changes to my daily routine would not interfere
with taking my medicines as prescribed
I have enough time to talk to the pharmacist at the pharmacy about my medication






Figure 3.9 provides a comparison between the responses to barriers from figure 3.1 and 
whether patients reported planning their further medicine use. Patients who reported planning 
their further medicine use were more likely to trust their doctor, more likely to get support 
taking their medicines and more likely to be able to solve any difficulties regarding their 
medicine regime. 
 
Figure 3.9 Comparison of patients who planned their further medicine use with patients 
who did not 





0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
I worry about the unwanted effects (e.g.
harmful effects or side effects) of taking my
medicines
I am confident that I could find ways to solve
any difficulties that I have with taking my
medicines as prescribed
If I needed support from others to take my
medicines as prescribed, I could get it
I trust my doctor(s) with decisions about my
healthcare
I know enough about my medicines to decide
whether to take them
I have a system in place to help me order,
collect and take my medicines as prescribed
Changes to my daily routine would not
interfere with taking my medicines as
prescribed
I made a plan with my doctor about my future medicine use






Figure 3.10 provides a comparison between the most frequent barriers in newly diagnosed 
patients (less than two years) and patients diagnosed for a longer time (two years or more). 
Fisher’s exact was used to test significant differences. Interestingly, there were no significant 




Figure 3.10 Comparison of the most frequent barriers between newly diagnosed patients 
and patients diagnosed for a longer time 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
I have enough time to talk to my doctor about my
medication
I have enough time to talk to the pharmacist at the
pharmacy about my medication
I have been requested to come to follow-up
consultations to discuss my medicine use
I know the risk of not taking my medication(s)
If problems appear with my medicine use (i.e forget
to take the, or get difficulties swallowing them) I
know where to get help
I am confident that I could find ways to solve any
difficulties that I have with taking my medicines as
prescribed
I worry about the unwanted effects (e.g. harmful
effects or side effects) of taking my medicines
Taking my medicines as prescribed is a burden to me
Taking my medicines as prescribed is an unwelcome
reminder of my condition
I remember to order and collect my medicines on
time
I trust my doctor(s) with decisions about my
healthcare
I know enough about my medicines to decide
whether to take them
Taking my medicine as prescribed does not fit with
my daily routine
I don't think I could cope if my medication regime
kept changing
Patients diagnosed for a longer time Newly diagnosed patients
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Table 3.2- 3.5 shows correlation between three statements; “I am motivated to take my 
medicines as prescribed”, “I intend to take my medicines as prescribed”, “I remember to take 
my medicines as prescribed” and the other barriers presented in this study. Correlations were 
tested to check if the three statements are important barriers to adherence. Spearman’s rank 
test was used to find correlations. 
 
Table 3.2 addresses “Information and follow-up of health personnel”. These statements are 
strongly correlated with the patient’s intentions of taking medicine. From the observed data, it 
seems like pharmacists have less influence than doctors on motivation, but have an equally 
strong influence as the doctor on the patient’s intention of taking medicines and having the 
ability to remember to take medicines. Patients having a good relationship with their doctor, 
being provided sufficient time to talk to their doctor, understanding why they need their 
medicines, expecting their medicines to work and understanding the risk of omitting their 
medicines are more likely to be motivated to take their medicines as prescribed. Patients who 
planned their further medicine use and had been requested to come to follow-up sessions with 
their doctor are more likely to intend to take their medicines as prescribed. The ability to 
remember to take medicines as prescribed is not as strongly correlated with information and 
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I expect my medicines to help 



















If problems appear with my 
medicine use (i.e. forget to take 
the, or get difficulties 
swallowing them) I know where 









I have been requested to come to 
follow-up consultations to 













Table 3.3 addresses the patients’ thoughts and attitudes about medicines. Motivation seems to 
be highly important regarding medicine thoughts and attitude. Patients motivated to take their 
medicines were more likely to intend to take their medicines as prescribed, and knowing the 
risk of omitting their medicines. Having negative emotions about taking medicines, feeling 
like medicines is a burden would less likely motivate the patients. Patients intending to take 
their medicines as prescribed were more likely to prioritise taking their medicines. Patients 
were not less likely to intend to take their medicines even though they were worrying about 
side-effects, thinking their medicines are a burden, thinking that their medicine is an 
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I have negative emotions (e.g. 
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# Spearman’s rank correlation * Significant at 0,05 level  ** Significant at 0,01 level 
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Table 3.4 addresses “Handling medicines”. Knowing how to take medicines as prescribed 
motivates the patients. Motivated patients may also have an increased chance of remembering 
to order and collect medicines on time. Patients intending to take their medicines as 
prescribed were more likely to know how- and remember to take medicines as prescribed and 
trust their doctor’s decisions. Medicine handling influenced the ability to remember to take 
medicines as prescribed more than the other topics, and the patients who reported being 
distracted from taking their medicines as prescribed were more likely to forget to take their 
medicines. Patients being physically able- and knowing how to- take medicines were more 
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I know enough about my 
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Table 3.5 addresses “Patient routines”. Within patient routines, motivation-, intention- and 
ability to remember- to take medicines as prescribed is influenced by the same barriers. These 
patients are more likely to have the information needed to easily order and collect 
prescriptions and feeling confident about managing medicines. The effectiveness at the 
pharmacy would more likely increase the patient’s intention to take medicines as prescribed 
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# Spearman’s rank correlation  * Significant at 0,05 level ** Significant at 0,01 level 
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3.2 Qualitative analysis of the comments from the questionnaire 
Four themes were identified from the written comments within the returned questionnaires 
and these are explained in Table 3.6. 
 
Table 3.6 Themes derived from written comments within returned questionnaires 
Category Description 
Information Comments on what type of information the patients got or 
what type of information they would want to have. 
Thoughts about medicines Patient attitudes and thoughts about taking medicines, either 
generally, concerning PD or side effects. 
Experiences and impression Patient experiences and impression of the health care 
system. 
Everyday life and medicines Comments about their medicine use in their daily lives. 
 
Information 
A major theme which arose from the written comments in the questionnaire was the need for 
better information, where side-effects was one important topic. 
“It’s important with information about side-effects (not just in a bisection).”      
(Patient 93). 
There has also been a focus on the lack of information about what medicines exist today and 
discussion with the patient about what treatment would be ideal for them. 
“I know the medications I use, but have no idea what is on the market or how they 
work / interact with other types. I would like to get information about what exists on 
the market and what medicines I can take together.” (Patient 100).  
 
Thoughts about medicines  
It seems that the patients have different views when it comes to taking medicines (Appendix 
B). Side-effects has been discussed by several patients, and seems to be an important part of 
what the patients focus on considering their medicine treatment.  
 “I use medicines with a lot and dangerous side-effects.” (Patient 56).  
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Experiences and impression 
As expected, patients have had several different experiences and impressions of the 
Norwegian health care system, where the topics; relationship with prescriber, having 
permanent neurologist or other health personnel, duration of consultation, contact with 
prescriber and follow-up have been mentioned. 
Patients seem to have different opinions about their prescriber. 
“I have been treated well by doctors and other health personnel in Haukeland 
hospital.” (Patient 34). 
“Unlucky with prescribing doctor/neurologist every visit.” (Patient 35). 
 
A permanent prescriber seems to be important as a part of their treatment, and may influence 
the patient’s ability to discuss their medicines further after their consultation is over. 
“At the half-yearly check at Haukeland, I never get the same neurologist. This makes 
the check difficult. If something happens to the medicines in the meantime (e.g. I was 
given too much medicine, became very ill 1 year ago) it is difficult for my doctor to 
contact a neurologist who knows me. There has also been given incorrect information 
about my medication back to the GP after visiting the polyclinic.” (Patient 73).  
 
The duration of the consultation is important for the patients to ask questions that may 
influence their adherence. This issue has been brought up by several patients. 
“It is frustrating to find that when one has met at the agreed consultation, they do not 
have time for me (…)  I feel that there is a lot I should have asked for, but that there is 
never time for it. Nor do I feel that I'm being taken seriously. It's all about following 
up the patient and making it easier for you to encounter problems.” (Patient 225). 
 
Patients have expressed different experiences regarding contact with their prescriber. 
“I got an additional medicine 2 years ago. I couldn’t use that because of stomach 




Patients have been requested follow-up consultations from their doctor on different levels. 
“There’s a problem that the hospital/ neurologist doesn’t have good enough routines 
for follow-up/ monitoring considering side-effects. Today’s lack of follow-up puts all 
risk on the patient.”  (Patient 63). 
“I am trying out new medicine. The doctor is going to follow up when the medicines 
have stabilised.” (Patient 40).  
 
Everyday life and medicines 
Within this topic, patients mostly commented on how their medicines affected their daily life, 
medicine administration difficulties and their thoughts about economy.  
Patients have stated their different thoughts of taking medicine in their daily life. 
“It can be hard to take Parkinson medication to meals, especially when I’m visiting 
my family that has different meal routines than we have at home.” (Patient 73). 
“The tablets are in strips with daily doses (5 daily) so it’s simple.” (Patient 153). 
 
When it comes to administration of medicines, the preferences are individual. 
“I take Medopar that is in a glass with cotton on top in a new container. The glass is 
hard to open, and it’s hard to remove the cotton. It should have been a blister 
package.” (Patient 42).  
“The new boards on "Sinemet" are difficult, easier tablet on glass. The tablets on the 
board are difficult to remove the entire tablet from the tray, they divide and crumble.” 
(Patient 85).  
 
The economic part of the treatment is important to consider as the patients have commented 
on this.  
“I use Duodopa. I get this covered 100%. If I had to pay it myself, I’d have to stop 
taking it.” (Patient 59).  
“I think that customers/patients that use a lot of medicines every day should be given 
doset on blue prescription.”  (Patient 109).  
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3.3 Qualitative analysis of focus group results 
One hospital pharmacist and one community pharmacist participated in the focus group 
together with the two researchers. There was no one in the room not participating in the focus 
group. The hospital pharmacist knew the moderator and the community pharmacist knew the 
facilitator prior to the study. Unfortunately, the neurologist failed to recruit health personnel 
working at the neurological ward at Haukeland, resulting that doctors and nurses were not 
able to attend thus resulting in a pharmacist-directed point of view. The focus group meeting 























Table 3.7 Main interventions discussed 
Theme Suggested actions 
Better information Group education. 
Medicine start (A new service in Norwegian pharmacies with follow-
up consultations for patients starting on a new medicine. Explained 
further in the discussion). 
Hand out short information leaflets 
More systematic follow-up on pharmacies concerning aids, offering 
different medicine containers if possible and practical handling of 
medicines. 
More active and focused information about side-effects 
Balanced amount of information about effect and side-effect 
Medicine review concerning side-effects 
Follow-up of side-effects in the hospital (by doctor, nurse or 
pharmacist). 
Use of time At hospitals: find out who can be used to give more patient-directed 
information in the most efficient way. 
Pharmacists can ease the work of both doctors and nurses by giving a 
larger quantity and more patient-directed information.  
Conversation skills Practice the consultation skills of pharmacists. 
Prioritise what information we want the patient to end up with. 
Find out what is important for the individual patient before starting 
the conversation. 
Practical actions Refer to appropriate websites. 
Use services to ease ordering medicines and use of multidose 









 4. Discussion 
4.1 Identified frequent barriers 
This is the first study to consider medication adherence post-discharge from hospital from the 
perspective of medication barriers and enablers. Generally, patients understood why they 
needed their medicines and expected them to work. The majority of the patients reported good 
relationships with their doctor. 
One of the main messages to be taken away from this was the belief that patients reported that 
they did not get enough time to talk to health personnel about their medicines. Interestingly 
this was a greater problem with pharmacists than doctors. Not all patients knew the risk of 
omitting their medicines, some patients have also stated that they have not planned their 
further medicine use-, and few patients have been requested follow-up sessions- from their 
doctor. Furthermore, if problems occurred patients did not know where to get help from. All 
of these issues could be addressed through consultations with doctors or pharmacists. 
Negative attitudes to medicines which are more difficult to address were perceptions of 
medicines being a burden, and an unwelcome reminder of their disease. Most patients are 
motivated to take medicines, but side-effects are a topic of concern and is supported by many 
of the comments from the questionnaire. Thankfully even with these views many patients 
stated that they intended to prioritise and take their medicines as prescribed.  
Knowing how to take medicines seemed not to be problem for most patients. In general, they 
were physically able to take medicines. Patients would not get help or solve difficulties 
regarding their medicine use if needed, indicating too little information about this. 
Unfortunately, insufficient information about their medicines was provided for the patients 
themselves to decide whether to take their medicines. This is supported by their comments. 
Healthcare professionals seem to provide enough information about ordering and collecting 
medicines and is therefore not a problem for most patients, even though few had a system to 
help manage their medicines. The economic aspect of their medicine regime scores low in the 
quantitative results. As commented, some patients struggle to fit their medicine regimen into 
their daily routine, and changing it (e.g. going on vacation), would influence their medicine 
adherence.  
It would seem that where patients reported having enough time with their doctor, the worry 
about side-effects decreased. Where patients reported having enough time with their 
pharmacist, the patient’s ability to solve problems increased. Patients who were satisfied with 
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the provided time to talk to healthcare professionals in general seemed to report increased 
trust in their doctor’s decisions about their healthcare and the ability to get support taking 
their medicines. 
Disease length did was not seen to relate to the barriers to non-adherence in this study, 
indicating that addressing non-adherence in patients diagnosed for a long time is just as 
important as newly diagnosed patients.  
Motivation-, intention- and ability to remember to take medicines are considered important as 
they relate to most of the barriers presented in this study. Patients who reported having 
enough time to talk to their doctor were more likely to be motivated than patients who 
reported having enough time with the pharmacist. Motivation correlated with many of the 
statements regarding medicine thoughts and attitude.  
Interestingly, there was no relation seen between the patient’s intention to take medicines as 
prescribed and the concern about side-effect or feeling that taking medicines is a burden or an 
unwelcome reminder. Nor did the patient’s intention to take medicines seem to relate to the 
patient having negative emotions about taking medicines. 
 
4.2 Strengths and limitations 
The longer since the consultation at the hospital, the bigger the risk of forgetting their 
thoughts about their medicine regime. If the consultation took place just before the arrival of 
the questionnaire, there is a risk that the patient has not developed a health behaviour or 
identified any barriers yet. With this in mind, we chose to include patients treated at the 
hospital from January to July 2017. 
 
Males are more likely to have PD than females because female genes and hormones have a 
neuroprotective effect (51, 52), and a higher proportion of males in the sample population is 
as anticipated. The response rate and gender distribution was reasonably similar to other 
studies using questionnaires of the same length, but the patients reported having the disease 
for a shorter period of time on average i.e. 6 years versus 8.6 (53-55). From these 
comparisons, the sample population seem to represent the general population of those with 




The response rate seems reasonable comparing to other literature, but a response rate below 
60% does raise questions regarding response bias and whether the non-responders and 
responders are similar. 
To improve response further we could have used several strategies (48): 
- Monetary incentives or non-monetary incentives 
- Unconditional incentives 
- Recorded delivery 
- A teaser on the envelope 
- Pre-notification 
- Follow-up contact 
- Providing a second copy of the questionnaire at follow up 
- Mentioning an obligation to respond 
- Personalised questionnaires 
- Use of hand-written addresses 
- First class outward mailing 
First class outward mailing is not relevant in the Norwegian mail system.  
 
We put a deadline in the pilot group, but decided to remove it because the letter arrived only 
one week before Christmas, thus assuming the respondents needed extra time to reply. The 
Cochrane review did not mention deadline to limit response rate in postal questionnaires (48). 
Since the response rate did not change, we assume that removing the deadline did not affect 
the response rate. 
 
The tool for this study is based on the Norwegian translation of the IMAB-Q, and is translated 
by the researchers (student and supervisor). The sample population responded well, 
suggesting the questionnaire was user friendly. However, we got several comments on the 
language while piloting the questionnaire, indicating that the translation was not ideal which 
affects face validity. There is a challenge translating and maintaining the original meaning 
and interpretation of the statement. The patients’ answers are then translated back to English 
for the analysis. The analysed data may vary slightly due to different interpretation of the two 
languages. Further recommendations would be to spend more time with patients to determine 
whether their interpretation and that of the researchers were the same. 
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The focus group was small, giving a lot of time for each participant to speak. The atmosphere 
in the group was good, and there was good flow in the conversation between the participants. 
As the focus group consisted only of pharmacists, the actions discussed are mainly concerning 
their task. Therefore, we cannot assume that the interventions are suited for all kinds of 
healthcare professionals. Participation by different kinds of professionals could provide a 
greater insight into how services could be changed to address the problems identified. Further 
focus group meetings consisting of neurologists, nurses, hospital pharmacists and community 
pharmacists should be performed to discuss the different interventions further.  
 
Some improvements of the questionnaire should be done in further studies. We should have 
specified what type of medicines we asked for in the questionnaire, as patients did not know 
whether to report all medicines or just medicines used for PD. We know this because some 
respondents commented on this question. These issues were not detected in the pilot study. 
Age could have been added along with disease length to the demographic questions of the 
questionnaire to help identifying the generalisability of the study population. Asking whether 
the patients got any help taking medicines would also be useful to know, as some of the 
questions would be irrelevant to them. As many patients misunderstood the question about 
economy “I do not have to choose between paying for my prescriptions and paying for other 
things that are important to me”, we should have clarified that patients getting medicines for 
free should not disagree with this statement. 
 
4.3 Discussion of main barriers 
There is a need for patients to provide enough information about where to get help if 
problems taking their medicines as prescribed appears, and where they can go to get help. 
Information about the risk of omitting their medicines also seems to be needed as this could 
increase non-adherence. Whilst doctors may not have time to provide all this information this 
provides an opportunity for pharmacists.  
 
Interestingly patients reported that they did not have as much time with a pharmacist as they 
would like. This was corroborated within the focus group by the community pharmacist. An 
insufficient number of community pharmacists in each pharmacy within Norway may 
partially explain this (56). However, it was also discussed in the focus group that hospital 
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pharmacies had less problems with time limit than community pharmacies. When insufficient 
time limits the pharmacist to provide information, they should focus on the risks of not taking 
the medicine and what the patient should do if problems arise. 
 
“Medicine start” is a new service in community pharmacies, where patients starting on a new 
medicines receives an opportunity of two follow-up consultations with a pharmacist (57). This 
is not established for all diseases yet, but this could be ideal for Parkinson patients where an 
optimal medicine routine could be established from the start. This service could attribute to 
the lack of follow-up the patients need, and could ease off the work of doctors. 
 
As discussed in the focus group, leaflets, webpages and apps can be useful to provide 
information and support patients to take their medicines. When time is crucial, this could 
seem like an efficient solution. However, older patients who cannot read the leaflets provided 
or use a computer or a smartphone cannot use this offer. Younger people are not likely to read 
the leaflet, resulting that no information has been comprehended. This intervention is 
suboptimal standing alone. 
 
It is reported from the patients in both the quantitative and qualitative results from the 
questionnaire that side-effects are a big concern. It is important that healthcare professionals 
identify patient concerns and address them. As discussed in the focus group, doctors, nurses 
or pharmacists at the hospital could provide follow-up sessions concerning side-effects. More 
active and focussed information about side-effects should be given in the pharmacies, as this 
is wanted by the patients (see appendix B).  
 
Feeling that taking medicines is a burden may cause non-adherence. Doctors could influence 
this barrier by easing the medicine regimen. Further research should be done on the effects of 
easing medicine regimen in patients with PD. Pharmacists can reduce burden by helping the 
patient structure their medicine regime, for example by taking their medicines at the same 




Not all patients trust their doctor’s decisions about their healthcare. This could be explained 
by the lack of knowledge about their own medicines, as many patients reported that they did 
not know enough about their medicines to decide whether to take them. Doctors could 
improve adherence by comparing the different medicines on the market focussing on effects 
and side-effects, giving the basis of making their own decisions when deciding the patient’s 
treatment. Pharmacists can also increase the patient’s trust in their doctor by confirming their 
choice of treatment and explaining why the treatment is important.  
 
Planning further medicine use and providing follow-up consultations could be a solution 
when patients have problems getting help or solve difficulties regarding their medicine 
regimen. Healthcare professionals could improve adherence by addressing the problems the 
patient is having, and find out how to solve them together with the patient. Follow-up sessions 
can be useful to allow the patient to seek help after having used medicines for a while. 
 
Almost two thirds of the study population stated that they did not have to choose between 
paying for medicines and paying for other important things. However, many patients 
commented their answers to this statement in the questionnaire. Due to the refund 
arrangement in Norway, many patients did not agree with the statement because they got their 
medicines for free. From the responses in the questionnaire, together with the comments, 
economy does not seem to be an essential barrier to non-adherence even though it is an 
important part of their medicine regimen. 
 
Incorporating a medicine regimen into their daily routine has been reported to be difficult. 
Changing routines (e.g. visiting family or going on vacation) seemed especially hard, and was 
corroborated in the comments from the patients, saying it was hard to remember to take 
medicines while visiting family. Planning medicine use with their doctor discussing what to 
do when their daily routine changes, could be ideal to reduce this barrier. Patients who just 
started taking medicines may not be ready to receive this kind of information right away, and 
would probably fit better in a follow-up consultation. Healthcare professionals could ask the 




From the results observed, there seems to be a difference in the doctor’s and pharmacist’s 
influence on the patients, which is expected as they have different tasks in the Norwegian 
healthcare system. Communication between healthcare professionals about interventions to 
non-adherence could reduce the barriers effectively. Patients should be directed to the right 
healthcare professional to improve adherence in the most effective way. 
 
Non-adherence seems to occur in patients regardless of the disease length. Healthcare 
professionals should address the necessity of identifying barriers to adherence in all patients, 
not just patients starting up on new medication. 
 
Motivation-, intention-and ability to remember- to take medicines as prescribed were assumed 
to be important regarding non-adherence. The tests indicate this assumption to be correct, as 
they correlated with most of the barriers presented in the questionnaire. Doctors should look 
for these factors in all patients when screening for non-adherence. Healthcare professionals 
should find out what the patient expects from the treatment, and ask them what they think is 














5.1 Identified frequent barriers 
This research has found that the patients intend to take their medicines as prescribed, and 
taking them is highly prioritised. Patients understand why they need their medicines, expect 
them to work, and know how to take them. From the observations provided, it seems like 
healthcare professionals influence the barriers to adherence in different ways. It is important 
to screen for motivation-, intention- and ability to remember- to take medicines as prescribed 
when addressing non-adherence in patients. Generally, screening for adherence seems to be 
important regardless of the disease length, as it seems to be unrelated to the barriers tested. 
 
The general areas for improvement are providing sufficient information and providing enough 
time to talk to healthcare professionals, as patients reported this to be insufficient. Few 
patients have been requested follow-up consultations from their doctor. Patients did not seem 
to have enough information to decide whether to take their medicines. Supported by the 
comments from the patients, worry about side-effects and not knowing where to get help 
taking their medicines seemed to be a problem. Some patients think that taking their 
medicines is a burden. 
 
5.2 Interventions to improve medicine non-adherence 
Having a time limit at community pharmacies seems to be a problem. Therefore, focussing on 
important information is necessary. When there is a lack of time, pharmacists should focus on 
prioritising informing about the risks of omitting their medicines and what to do if problems 
arise as this information seems to be needed. Providing balanced and specific information 
about side-effects could also be beneficial as this information seems to be wanted. Healthcare 
professionals could reduce the concerns about side-effects by identifying and addressing 
them. Comparing the different medicines on the market and explaining the benefit of the 
chosen treatment could increase the patient’s trust in their doctor. Easing- or structuring- the 
medicine regimen could contribute to reduce the burden taking medicines, and if other 
problems appear (e.g. taking medicines on vacation), it is important to address them, plan 
further medicine use to cope with them or address them in follow-up consultations. As 
different kinds of healthcare professionals perform different tasks, it is important to direct the 
patient to the right healthcare professional to improve non-adherence in the most effective 
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way. When necessary, healthcare professionals should address non-adherence in all patients, 
not just newly diagnosed patients. Asking them what they expect from the treatment and what 
they find important could be ideal to improve their motivation to take their medicines as 
prescribed.  
 
5.3 Further research 
More studies should be done identifying barriers to medicine non-adherence in PD patients, as 
there are few studies covering this topic. Providing in-depth studies regarding individual 
barriers discussed in this study would be ideal for discussing correlations with other barriers 
leading to non-adherence. More work is required to identify the most appropriate behaviour 
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Appendix A: Translated questionnaire 
Medisinbruk hos personer med Parkinsons eller Parkinsonisme 
Hei! 
Jeg er en mastergradsstudent i farmasi ved Universitetet i Bergen.  
I forbindelse med masterprosjektet mitt vil jeg finne ut hvilke ting som hjelper personer med 
parkinson eller parkinsonisme å ta medisinene sine og hvilke ting som gjør det vanskeligere. 
Disse anonyme resultatene vil jeg dele med ansatte på Haukeland sykehus, slik at de kan 
hjelpe på best mulig måte med medisinene sine mens de er på sykehuset. 
Svarene fra deltakere er nyttig for å hjelpe oss å forstå hvordan vi kan hjelpe deg til å ta 
medisinene dine hjemme. Informasjonen jeg får vite vil bli presentert i eventuelle 
publikasjoner som blir utgitt. 
Dette studiet vil ikke direkte påvirke deg, men det kan hjelpe andre personer med disse 
sykdommene i fremtiden. 
 
Bare spørreskjemaet sendes tilbake i vedlagte svarkonvolutt. Svarfrist: 20. desember 2017 
• På hvert spørsmål skal du krysse av (x) i boksen som på best måte reflekterer hvor 
stor grad du er enig/uenig i påstandene. Det skal bare krysses av i én boks for hvert 
spørsmål. Noen av påstandene kan virke like, men det er viktig å svare på hver enkelt 
påstand. 
• Spørreskjemaet vil hjelpe oss å forstå mer om eventuelle utfordringer du kan ha når 
du tar medisinene dine.  
• Det er ingen riktige eller gale svar. Vi er interesserte i ditt ærlige syn på egen 
medisinbruk. 
• Svarene du gir er helt anonyme og kan ikke spores tilbake til deg. 
• Spørreskjemaet består av 43 spørsmål, og det tar ca. 10-15 minutter å fylle ut. 
 
 
Denne studien er godkjent av REK (Regionale komiteer for medisinsk 
og helsefaglig forskningsetikk). 01.09.17- Etterlevelse av personer 
med Parkinson sykdom. 
Tusen takk for hjelpen!                    
 Med vennlig hilsen                                                                             
Kine Sola Flagstad, student, Universitetet i Bergen (UiB) 
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Medisinbruk hos personer med 





• På hvert spørsmål skal du krysse av (x) i boksen som på best måte reflekterer hvor stor 
grad du er enig/uenig i påstandene.  
• Det skal bare krysses av i én boks for hvert spørsmål.  
• Noen av påstandene kan virke like, men det er viktig å svare på hver enkelt påstand. 
• Bruk vedlagte svarkonvolutt ved retur. 




Informasjon og oppfølging fra helsepersonell 
 
 
 Du og medisinene dine  
 
 Utsagn Helt 
enig 




10 Jeg vet hvordan jeg skal ta medisinene mine som avtalt med lege      
11 Jeg er i fysisk stand til å ta medisinene mine      
12 Jeg husker å ta medisinene mine slik det står skrevet på 
bruksanvisningen på pakken  
     
13 Jeg stoler på at legemiddelbehandlingen er godt tilpasset meg      
14 Det er enkelt å hente medisinene mine fra apoteket      
15 Jeg blir frustrert, flau, lei, sint av å ta medisinene mine      
16 Jeg er motivert til å ta medisinene mine      
17 Jeg har råd til å betale for medisinene mine, og det går ikke utover 
andre ting som er viktig for meg 
     
 Utsagn Helt 
enig 




1 Jeg har et godt forhold til legen(e) jeg har fått medisin fra      
2 Jeg føler jeg har god nok tid til å snakke med legen om medisinene 
mine 
     
3 Jeg føler jeg har god nok tid til å snakke med farmasøyten på 
apoteket om medisinene mine 
     
4  Jeg har blitt enig med legen om en plan om medisinbruken 
fremover 
     
5 Jeg forstår hvorfor jeg trenger medisinene mine       
6 Jeg forventer at medisinene mine vil hjelpe meg mot sykdommen 
min 
     
7 Jeg vet hvilken risiko jeg kan forvente dersom jeg ikke tar 
medisinene mine 
     
8 Jeg har blitt oppfordret til å komme til oppfølgingstimer for å 
diskutere medisinbruken min 
     
9 Hvis det oppstår problemer med å ta medisinene mine (f.eks. 
glemmer å ta dem eller får problemer med å svelge dem), vet jeg 
hvor jeg kan få hjelp. 
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 Utsagn Helt 
enig 




18 Jeg synes det generelt går greit å fornye resepter, hente og ta 
medisinene mine  
     
19 Jeg bekymrer meg for uønskede virkninger (f.eks. bivirkninger, 
skadelige virkninger) av å ta medisinene mine 
     
20 Jeg kan tilstrekkelig mye om medisinene mine til å bestemme om 
jeg skal ta dem eller ikke 
     
21 Jeg bruker alarm, dosett, andre hjelpemidler eller får hjelp til å 
bestille, hente og ta medisinene mine 
     
22 Jeg glemmer ofte å ta medisinene mine      
23 Hvis jeg trenger hjelp for å ta medisinene mine på rett måte, vet jeg 
hvor jeg får det 
     
24 Mine daglige rutiner vil påvirke hvordan jeg tar medisinene mine       
25 Å ta medisinene mine er en uønsket påminnelse om sykdommen 
min  
     
26 Å ta medisinene mine er viktig for meg/er høyt prioritert      
27 Å ta medisinene mine slik det står på bruksanvisningen på 
medisinpakken passer ikke inn i hverdagen min  
     
28 Hvis det skulle oppstå problemer med å ta medisinene mine kan jeg 
finne en måte å løse det på 
     
29 Hvis jeg ikke tar medisinene mine som avtalt med legen, tror jeg 
helsetilstanden min vil bli verre 
     
30 Jeg har den informasjonen jeg trenger for enkelt å fornye resepter 
og hente medisinene mine 
     
31 Det er ikke et problem for meg å se forskjell på de ulike medisinene 
mine 
     
32 Jeg husker å bestille og hente medisinene mine tidsnok slik at jeg 
har de legemidlene jeg trenger 
     
33 Jeg bekymrer meg over hva andre måtte tenke hvis de visste at jeg 
tar medisiner 
     
34 Apoteket jeg bruker sørger for en god og rask ekspedering av 
medisinene mine  
     
35 Jeg synes det er en byrde å ta medisinene mine      
36 Jeg prøver alltid å ta medisinene mine som avtalt med legen      
37 Hverdagen min gjør det vanskelig å ta medisinene mine som avtalt 
med legen 
     
38 Jeg tror ikke jeg kunne greid å ta medisinene mine riktig dersom 
behandlingen min skulle endre seg 
     
39 Jeg har mine grunner for at jeg ikke tar medisinene mine som avtalt 
med legen 






40) Kjønn          Mann    Kvinne  
 
41)  Hvor lenge har du hatt sykdommen? ___________ år 
 
42)  Hvor mange forskjellige typer medisiner bruker du?   ____________  
 
43)  Har du noen kommentarer utover svarene på spørsmålene på spørreskjema?  
• Er det noe mer vi burde spurt om? 
• Er det noen andre ting vi kunne ha gjort bedre på sykehuset eller apotek for å hjelpe 
deg å ta medisinene dine? 
• Har du noen spesielle ting du vil si om medisinene dine eller spørreskjemaet? 




















Takk for hjelpen! 
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Appendix B: Patient comments translated from Norwegian 
1. Information 
2. Thoughts about medicines 
3. Experiences and impression 
4. Everyday life and medicines 
 
1. Information 
1.1 Information about side-effects 
Patient 20 
I wish I got more information about side-effects.  
Patient 42 
I have experienced a lot of side-effects from my medicines. Because of this, I’ve had to 
change my medicines. This is on my own initiative. I would like if the Pharmacy would 
inform me that if I experience unwanted side-effects, I should contact my doctor to change the 
dose or medicine. 
Patient 93 
It’s important with information about side-effects (not just in a bisection).  
Patient 191 
I don’t know what the combination of the side- effects can lead to.  
 
1.2 Information about disease and medicines 
Patient 28 
I have done deep brain surgery (DBS) about 4 years ago. I would like information about how 
many medications I’d have to take, even though I was operated.  
Patient 42 
I think it’s important that the pharmacy staff tell me what medicines I should take without 





You must simply apply to the Parkinson’s association to be updated (possibly new things).  
Patient 55 
They should hand out a floppy disk/ CD that could be downloaded on a computer that 
reminds/ alert which medicines I had taken for the day. I have 6 different Parkinson-, heart 
medicine/blood thinners. Sometimes I wonder what I have taken and what I have forgot (I 
assume a lot of patients feel the same).  
Viagra in combination with Parkinsons/blood thinners.  
Group seminars, light up/explains myths about the disease. NRK (Norwegian broadcasting 
corporation)/ media always tell us about “major improvements”. If they invited 50-100 people 
multiple times a year, could help giving answers that we wouldn’t get in half an hour in 
everyday life. As I have understood, there’s a lot of competent specialists, send invitation! 
Patient 100 
I know the medications I use, but have no idea what is on the market or how they work / 
interact with other types. I would like to get information about what exists on the market and 
what medicines I can take together.  
Patient 113 
I think it there is one-sided information about my medicine in my treatment.  
Patient 123 
I haven’t been given information, and guidance about the disease. Read about it myself.  
Any good vision ahead? New medicines with less side-effects? Could one have extra 
medicine besides the ones dosed when needed. 
Conversation with pharmacist? 
Patient 134 







I miss that the doctor gives very little information about the disease, and information about 
things I can do myself. That it’s important to exercise regularly, and that I have the right for 
physiotherapy. After a while I have been getting information (for instance the Parkinson 
association) has done a lot of work with this.  
Patient 187 
I don’t know anything about medication, but I have to believe that the doctor does what’s best 
for me. 
Patient 213 




















2. Thoughts about medicines 
2.1 Attitudes for medicines 
Patient 51 
The medications I take seem to work well. 
Patient 53 
I have to take medicines for 3 different chronic diseases: glaucoma, angina and parkinson. I 
think that’s a lot. I have always been restrictive trying out new medicines. I think a lot about 
side-effects.  
Patient 62 
Don’t be afraid to take medicines. That’s just something we need to do well.  
Patient 76 
I have an imbalance in my body, but there is nothing that helps. 
Patient 81 
My medicine use is going well. 
Patient 117 
I don’t know how much my medicine is helping me, i.e. how my progression of my disease 
had been without my medicines.  
Patient 225 
I have no experience with pharmacists. I am fully aware that I need medicines and that it is 
important to take them. And what the consequences are if I don’t take them. BUT, there are 
also side effects to take into account. And with bad follow-up and often diffuse information 








2.2 Thoughts about side-effects 
Patient 17 
I think a lot of people doesn’t like the medicines, gas and pain, leading to little uptake. That 
varies in the day.  
Patient 20 
I’m tired, and fall asleep easily when we are out. Not fun. 
Patient 45 
I don’t think I have Parkinson’s disease. After the GP lowered the use of Sinemet, I have 
gotten a better sense of taste, men most things (except sweet things) still taste like 
“crispbread”. 
Patient 56 
I use medicines with a lot and dangerous side-effects. 
Patient 73 
I can suddenly get very sleepy after intake of dopamine, something that, amongst other things, 
leads to that I can’t drive a car anymore.  
Patient 110 
Side-effects of the medicines. A lot of bowel and stool problems. 
Patient 155 
I have stopped taking addition medicine (Elderyl) which gave me major side-effects like 
suicidal dreams. I stopped the medicine in consultation with my doctor. I am much better 
now.  
Patient 163 
My medicines give me bothering side-effects like dry mouth. 
Patient 172 
Side-effects creates uncertainty.  
Patient 206 
I am dizzy quite often. I think that’s because of the pills, but I don’t know if it comes from 




Have experienced abstinence after reducing the dose of Sifrex. Medications affect sleep-pain-
sex- impulse control. 
Patient 214 
























3. Experiences and impression 
3.1 Thoughts and relationships with prescriber 
Patient 34 
I have been treated well by doctors and other health personnel in Haukeland hospital.  
Patient 35 
Unlucky with prescribing doctor/neurologist every visit. 
Patient 50 
I want to try out asthma medicine that is discussed in media, but both my GP and specialist 
tell me that there aren’t enough trials yet. I can’t be a “trial subject”, even though I want to. 
My parkinson is by now tremor in my left hand, but often bothers me. 
Patient 104 
Do you get help/support every day? 
Patient 224 
It is a known matter that it is a big problem to get medications that work as desired. 
 
3.2 Permanent healthcare professionals 
Patient 12 
The home nurse care should have regular people seeing them, so that they don’t have to start 
all over again every time. Regular staff gives safety to patients. They need to see that treating 
Parkinson with medicines is important for other kind of healings also.  
Patient 73 
At the half-yearly check at Haukeland, I never get the same neurologist. This makes the check 
difficult. If something happens to the medicines in the meantime (e.g. I was given too much 
medicine, became very ill 1 year ago) it is difficult for my doctor to contact a neurologist who 
knows me. There has also been given incorrect information about my medication back to the 
GP after visiting the polyclinic.  
Patient 77 




It’s a dilemma that there are different doctors at neurology ward every time I’m there. I miss a 
permanent doctor.  
Patient 184 
What frustrates me is that I don’t have any permanent doctor. I have only met each doctor 2 
times, then there’s a new doctor.  Someone I’ve just met 1 time.  
Patient 195 
Now I have a permanent neurologist. At Haukeland there were constantly new ones (6-7 
different) that had different “medicine politics”.  
Patient 225 
At Haukeland Hospital there are still new doctors to relate to, as far as I get consultation there. 
 
3.3 Duration of consultation 
Patient 19 
It seems like the neurologists at the hospital are busy. 
Patient 52 
We, who live on the countryside, think it’s difficult to travel the whole day to have a 15 
minute consultation. There’s no guarantee that the doctor contact after an mhi reference.  
Patient 100 
I have too little time at the doctor/ neurologist.  
Patient 195 
At St. Olav I get plenty of time at the consultation; in Haukeland I often get too short time. At 
Haukeland the doctors didn’t know my situation/ variant well enough. 
Patient 225 
It is frustrating to find that when one has met at the agreed consultation, they do not have time 
for me (…)  I feel that there is a lot I should have asked for, but that there is never time for it. 
Nor do I feel that I'm being taken seriously. It's all about following up the patient and making 





Censurable that I haven’t heard from St. Olavs hospital in a whole year. 
Patient 52 
I heard nothing after my visit in the neurological ward, Haukeland.  
Patient 77 
I got an additional medicine 2 years ago. I couldn’t use that because of stomach issues. But I 
never get to give feedback.  
Patient 79 
I am a very new patient, so I haven’t thought about my questions yet, but I have good contact 
with my GP.  
Patient 133 
The neurologic ward was going to make me another consultation after half a year. Now it’s 
almost been a year since last time, but I still haven’t gotten a consultation.  
Patient 163 
If I feel that I need to talk to the doctor (neurologist) it takes a bit long before I will get a 
consultation.  
Patient 211 




I am trying out new medicine. The doctor is going to follow up when the medicines have 
stabilised.  
Patient 46 





There’s a problem that the hospital/ neurologist doesn’t have good enough routines for 
follow-up/ monitoring considering side-effects. Today’s lack of follow-up puts all risk on the 
patient.  
Patient 123 
Good follow-up by neurologist? – no 
Good follow-up by GP- yes 
Patient 195 
I have been doing surgery (deep brain stimulation) at St. Olavs Hospital, and get followed up 
there 1 session pr. Year, including medicine use. This follow-up is substantially better than in 
Haukeland. 
Patient 225 
Usually have consultation half-yearly. When it's not a follow-up session, I think it's too bad. 
Have experienced being "forgotten" - when the time for new consultation was there and I 
heard nothing from there. Had to call and ask for a new consultation.  
I have never been offered any follow-up hours either by a GP or a neurologist. This has to be 
done and I hope there are not many who have experienced this. When I have been with a 
neurologist, I get a new notice for a new consultation about half a year later. I do not call this 
follow-up especially if there was done was a change of medication. I should then expect the 












4. Everyday life and medicines 
4.1 Handling medicines 
Patient 62 
If I forget to take a necessary medicine (in the morning), I can feel discomfort after. Then it’s 
smart to have an extra medicine (pill) “in my pocket”.  
Patient 73 
It can be hard to take Parkinson medication to meals, especially when I’m visiting my family 
that has different meal routines than we have at home.  
Patient 93 
“Intravenous” medicine would help me take the medicine at the right time.  
Patient 153 
The tablets are in strips with daily doses (5 daily) so it’s simple. 
Patient 186 
The nursing home has the responsibility for my medicines. Sometimes errors still occurs.  
Patient 206 
The nursing home has taken a lot of the responsibility. They arrive with medicine bags, 
already dosed, and they come at inspections to check if I take the pills as agreed.  
Patient 228 
The Duodopa pump I have used since 2012 is far too big, heavy and inconvenient. Here must 
be a huge development potential! A book could be written about everything I've experienced 
and had to find a solution to the handling of the pump and its belongings! 
 
4.2 Medicine access 
Patient 195 
Last summer I forgot my medicines, going to a cabin. I got Sinemet from the pharmacy in 
Geilo, but I didn’t have any Oprymea left on my prescription. The pharmacist said that a 





Medicines are administrated by home nursing 6 times a day. Changes are hard to 
communicate into this service. 
 
4.3 Physical ability to take medicines 
Patient 42 
I take Medopar that is in a glass with cotton on top in a new container. The glass is hard to 
open, and it’s hard to remove the cotton. It should have been a blister package. 
Patient 85 
The new boards on "Sinemet" are difficult, easier tablet on glass. The tablets on the board are 
difficult to remove the entire tablet from the tray, they divide and crumble. 
Patient 168 
Swallowing reflex, I have gotten small single-use juice bags that can be used to help people 




I use Duodopa. I get this covered 100%. If I had to pay it myself, I’d have to stop taking it.  
Patient 71 
Without a refund from the state, Duodopa medicine would be out of question.  
Patient 100 
I think the doctor/ neurologist has his/her commissions on some pills and prescribes these. 
Patient 109 
I think that customers/patients that use a lot of medicines every day should be given doset on 
blue prescription.   
Patient 150 





What about asthma medicine? When will that come? 
Patient 206 
The new system (multidose) is effective, but NO for plastic bags! 
 
